Comparison Between Two Different Dosages of Remifentanil During Colonoscopy
Information source: Ospedale San Raffaele
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Colonoscopy
Intervention: Remifentanil (Drug); Remifentanil (Drug); Meperidine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Ospedale San Raffaele
Summary
The purpose of this randomized double-blind trial is to define the correct dosage of
Remifentanil during operative and diagnostic endoscopic procedures. In particular we want to
analyze if the administration of Remifentanil by PCSA (Patient Controlled Sedation and
Analgesia) is a good method during colonoscopy, evaluating pain control, discharge time and
side effects.
90 patients undergoing colonoscopy will be enrolled.
Clinical Details
Official title: Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care
Primary outcome: Discharge Time, the Time to Reach a Modified Aldrete Score ≥18
Secondary outcome: Patient's Satisfaction
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult Patients
- Diagnostic and Operative Colonoscopy
- ASA Physical Status I-II
Exclusion Criteria:
- Age < 18 years
Locations and Contacts
San Raffaele Hospital, Milan 20132, Italy
Additional Information
Starting date: April 2009
Last updated: January 2, 2012
|
